Issue Date: August 15, 2011
Pipeline Payoff Helps Pharma
If the first quarter of 2011 was all about promises of things to come, the second quarter saw some actual results. Many of the major pharmaceutical companies focused their recent earnings reports on new products and new markets for them. At the same time, they continued to make cuts in light of generics competition.
Novartis was among those bearing the most fruit. The Swiss company reported four new product approvals in the quarter, giving . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society